证券代码：002603 证券简称：以岭药业 公告编号：2023-038 石家庄以岭药业股份有限公司 关于参加 2023 年河北辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，石家庄以岭药业股份有限公司（以下简称 "公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景网络有限公司联合 举办的"2023 年河北辖区上市公司投资者网上集体接待日活动"，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本 次互动交流，活动时间为 2023 年 5 月 30 日（周二）15:00-17:00。届时公司高管将在 线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和 可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 石家庄以岭药业股份有限公司 董事会 2023 年 5 月 26 日 ...

证券代码： 002603 证券简称：以岭药业 石家庄以岭药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|----------------------------------|----------------------------|--------------------| | | | | 编号：20230518 | | 投资者关系活动 | □特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 √ | 业绩说明会 | | | | □ 新闻发布会 | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 | | | | 人员姓名 | | | | | 时间 | 2023 年 5 月 18 日 ( | 周四) 下午 15:00~17:00 | | | 地点 | | | https://ir.p5w.net | | | 采用网络远程的方式召开业绩说明会 | | | | 上市公司接待人 | 1、董事长兼总经理吴相君 | | | | ...

Financial Performance - The company's revenue for Q1 2023 reached CNY 3,934,956,597.43, representing a 44.56% increase compared to CNY 2,721,951,194.99 in the same period last year[3] - Net profit attributable to shareholders was CNY 1,202,514,384.13, a significant increase of 148.29% from CNY 484,315,677.33 year-on-year[3] - The basic earnings per share rose to CNY 0.72, up 148.28% from CNY 0.29 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 3,934,956,597.43, a significant increase of 44.7% compared to CNY 2,721,951,194.99 in the same period last year[17] - Net profit for Q1 2023 was CNY 1,201,436,813.41, representing a year-on-year growth of 148.3% from CNY 483,506,718.16[18] - Earnings per share for Q1 2023 were CNY 0.72, up from CNY 0.29 in Q1 2022, indicating a substantial increase in profitability[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,246,700,806.38, an increase of 11.70% from CNY 16,336,112,689.27 at the end of the previous year[3] - Total liabilities increased to CNY 6,114,648,032.17 in Q1 2023, up from CNY 5,405,840,867.59 in the previous year, marking a rise of 13.1%[16] - The total non-current assets reached CNY 9,786,704,237.57, an increase from CNY 9,081,925,407.83 year-on-year, reflecting a growth of 7.7%[16] Cash Flow - The company's cash flow from operating activities decreased by 26.61% to CNY 400,342,932.75, down from CNY 545,481,950.73 in the same period last year[3] - The cash inflow from operating activities for the current period was CNY 3,722,327,089.52, an increase of 47.1% compared to CNY 2,529,899,387.91 in the previous period[20] - The net cash flow from operating activities decreased to CNY 400,342,932.75 from CNY 545,481,950.73, representing a decline of 26.5%[20] - The cash outflow from investing activities was CNY 2,407,993,111.75, significantly higher than CNY 165,483,895.60 in the previous period[21] - The net cash flow from investing activities was negative at CNY -1,464,282,378.84, compared to CNY -164,849,718.98 in the previous period[21] - Cash inflow from financing activities was CNY 200,000,000.00, down from CNY 699,902,000.00 in the previous period[21] - The net cash flow from financing activities improved to CNY 193,768,027.01 from CNY -112,615,463.58[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 257,051[10] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of the shares, totaling 526,775,963 shares[10] - The top ten shareholders include several individuals with significant stakes, including Wu Xiangjun with 20.81% and Wu Rui with 2.34%[10] Operational Efficiency - The company reported a gross profit margin of approximately 65.0% for Q1 2023, compared to 61.5% in the same quarter last year, showing improved operational efficiency[17] - Research and development expenses for Q1 2023 were CNY 164,844,076.56, slightly higher than CNY 158,060,812.51 in Q1 2022, indicating continued investment in innovation[17] Market and Product Development - The company has not disclosed any new product or technology developments in the current report[12] - There are no indications of market expansion or mergers and acquisitions mentioned in the current financial report[12] - The company plans to expand its market presence and invest in new product development to sustain growth momentum in the upcoming quarters[18] Inventory and Receivables - The company reported a 39.58% increase in inventory, reaching CNY 2,822,132,114.80, attributed to increased production scale[8] - Inventory levels rose significantly to ¥2,822,132,114.80 from ¥2,021,821,524.20, an increase of approximately 39.7%[14] - Accounts receivable increased to ¥1,938,660,386.86 from ¥1,726,806,702.36, reflecting a growth of about 12.2%[14]

Financial Performance - The company's operating revenue for 2022 was approximately ¥12.53 billion, representing a year-on-year increase of 23.88% compared to ¥10.12 billion in 2021[22]. - The net profit attributable to shareholders for 2022 reached approximately ¥2.36 billion, a significant increase of 75.75% from ¥1.34 billion in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥2.32 billion, up 83.68% from ¥1.26 billion in the previous year[22]. - The net cash flow from operating activities surged to approximately ¥3.49 billion, marking a remarkable increase of 559.69% compared to ¥528.69 million in 2021[22]. - The basic earnings per share for 2022 was ¥1.4137, reflecting a 75.75% increase from ¥0.8044 in 2021[22]. - The total assets at the end of 2022 amounted to approximately ¥16.34 billion, an increase of 26.59% from ¥12.90 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥10.93 billion, up 20.54% from ¥9.07 billion at the end of 2021[22]. - The company reported a weighted average return on equity of 23.62% for 2022, an increase of 8.68% from 14.94% in 2021[22]. - The total revenue for the year 2022 was approximately 12.51 billion yuan, with a year-on-year growth of 5.9%[35]. - The company's total operating costs for 2022 were ¥4,526,601,093.25, with a gross profit of ¥7,993,201,258.39[173]. Market Position and Strategy - The company is positioned in a weak cyclical industry, which is less affected by macroeconomic fluctuations, ensuring stable demand[37]. - The ongoing healthcare reforms and increased government support for traditional Chinese medicine are expected to enhance market opportunities for the company[38]. - The company plans to leverage its strengths in traditional Chinese medicine to capture a growing market driven by aging populations and rising health awareness[36]. - The company ranked 6th in the "2021 China Traditional Chinese Medicine Enterprises TOP 100" list, showing a steady improvement from the previous year[45]. - The company has established a comprehensive health industry system, integrating medical, pharmaceutical, health, and wellness services, with a focus on traditional Chinese health concepts[59]. - The company has established a comprehensive academic marketing network across the country, targeting various healthcare sectors to promote its products effectively[88]. - The company has a strong focus on the integration of traditional Chinese medicine and Western medicine in treating chronic diseases[98]. Product Development and Innovation - The approval of 7 new traditional Chinese medicine products by the National Medical Products Administration in 2022 indicates a growing trend in innovation and development within the industry[41]. - The company has developed 13 patented new drugs, focusing on major diseases with high incidence rates, including cardiovascular, endocrine, respiratory, tumor, neurological, and urinary diseases[56]. - The company has established a new model for TCM innovation that combines theory, clinical practice, and new drug development, contributing to the advancement of TCM[72]. - The company is actively involved in the development of guidelines and consensus documents for various diseases, showcasing its commitment to evidence-based medicine[98]. - The company has established a clinical cooperation base with Hebei Yiling Hospital, which supports the transformation of new drugs and enhances its research capabilities[92]. - The company has received numerous awards, including 1 National Science and Technology Progress First Prize and 4 Second Prizes, along with over 300 traditional Chinese medicine invention patents[57]. Clinical Research and Efficacy - The clinical evidence shows that Shensongyangxin capsules significantly reduce the occurrence of premature beats and improve symptoms in patients with arrhythmias[67]. - A clinical trial demonstrated that Qiliqiangxin capsules significantly lowered NT-proBNP levels by 30% in chronic heart failure patients, outperforming the control group[69]. - The results of the Qiliqiangxin study were published in the Journal of the American College of Cardiology, highlighting its reliable efficacy in heart failure treatment[70]. - The company has completed 28 large-scale clinical evidence studies and is conducting 8 ongoing studies to validate the efficacy of its existing products[127]. - The company has published findings from a study on Lianhua Qingwen in the journal Phytomedicine, providing scientific evidence for traditional Chinese medicine in combating COVID-19[130]. Sales and Marketing - The company has established a comprehensive sales network covering over 100,000 medical terminals and 300,000 pharmacies nationwide, ensuring strong competitive advantage[100]. - The company has signed strategic cooperation agreements with JD Health and Alibaba Health to promote business development and transition from pharmaceutical sales to health product sales[158]. - The company has been recognized as a provincial-level e-commerce demonstration enterprise in 2022, reflecting its strong online business capabilities[158]. - The marketing strategy leverages the unique differentiation of the company's products based on the theory of meridian diseases, enhancing recognition among target customers[88]. Research and Development - The company has a robust R&D framework with various innovation platforms, including national technology centers and key laboratories, to drive future innovation[102]. - The company has applied for 422 patents related to 13 patented traditional Chinese medicines, with 267 effective authorized patents, enhancing product lifecycle protection[104]. - The company’s R&D investment reached 89,547.22 million yuan, accounting for 7.15% of its operating revenue, which is above the industry average[159]. - The company is focusing on academic promotion and optimizing sales management to improve market coverage and share[112]. Financial Management - The company has adopted a prudent investment strategy to ensure the effectiveness of fundraising usage[196]. - The company has utilized bank acceptance bills to pay for fundraising investment projects totaling 192.75 million CNY[197]. - The company temporarily supplemented working capital with 45,000 million CNY, which was fully returned to the special account by July 2022[197]. - The company has established a dedicated intellectual property management department to strengthen patent protection and management strategies[103].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）定于 2023 年 5 月 18 日 下午 15：00-17：00 在全景网举办 2022 年度网上业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：董事长兼总经理吴相君先生、财务负责人李 晨光先生、董事会秘书吴瑞女士、独立董事韩志国先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 17 日 12：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集 专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回 答。 欢迎广大投资者积极参与。 特此公告。 证券代码：002603 证券简称：以岭药业 公告编号：2023-034 石家庄以岭药业股份有限公司 关于举 ...